PMID- 15549587
OWN - NLM
STAT- MEDLINE
DCOM- 20050207
LR  - 20191210
IS  - 1341-9625 (Print)
IS  - 1341-9625 (Linking)
VI  - 9
IP  - 5
DP  - 2004 Oct
TI  - Noninvasive detection of alterations in chromosome numbers in urinary bladder 
      cancer cells, using fluorescence in situ hybridization.
PG  - 373-7
AB  - BACKGROUND: Bladder cancers have a high potential for recurrence and sometimes 
      become invasive even in superficial cases. In this process, gene mutations in 
      tumor suppressor genes such as p53, on chromosome 17, or p16, on chromosome 9, 
      are thought to be important. In order to investigate whether the detection of 
      alterations in chromosome number might be used as an alternative to invasive 
      techniques for the assessment of clinical bladder cancer, fluorescence in situ 
      hybridization (FISH) was employed to analyze chromosome numbers in a series of 
      patients. METHODS: A total of 40 patients with transitional cell carcinomas 
      (stages Ta to T4, including carcinoma in situ [CIS]) were examined for abnormal 
      numbers of chromosomes 9 and 17, by FISH, using 41 and 42 samples of voided 
      urine, respectively. Tumor grades were as follows: G1:G2:G3 = 4:21:17. Urinary 
      cytology and presence of bladder tumor antigen (BTA) were also checked in the 
      same samples. One hundred cells were examined in each sample, and abnormality was 
      concluded to be present when more than 20% of cells demonstrated polysomy 
      (defined as three or more chromosomes). RESULTS: Seventeen of 41 samples (41.5%) 
      were abnormal with regard to chromosome 9, and 17 of 42 (40.5%) were abnormal for 
      chromosome 17. Both chromosomes were affected in 13 cases, of which 8 were 
      positive for urinary cytology and BTA. Univariate analysis, performed with 
      urinary cytology, BTA, tumor grade, tumor stage, involvement of vessels, pattern 
      of invasion, number of tumors, and prognosis as parameters, demonstrated a 
      significant influence of urinary cytology (P = 0.0368 and P = 0.0278 for 
      chromosomes 9 and 17, respectively), BTA (P = 0.0094 for chromosome 17), 
      involvement of vessels (P = 0.0262 for chromosome 17), pattern of invasion (P = 
      0.0028 and P = 0.0327 for chromosomes 9 and 17), grade (P = 0.0213 and P = 0.0174 
      for chromosomes 9 and 17), and stage (P = 0.0457 for chromosome 17). All the 
      other parameters also tended to be linked with the changes in chromosomes, except 
      for tumor number. Multivariate analysis demonstrated significant differences for 
      tumor grade (P = 0.0166) and pattern of invasion (P = 0.0006) for chromosome 9. 
      CONCLUSION: Voided-urine FISH is an effective noninvasive method for the 
      detection of altered chromosome numbers in bladder cancer cells, and may provide 
      an indication of tumor progression when combined with urinary cytology and BTA.
FAU - Okamura, Takehiko
AU  - Okamura T
AD  - The Urology Division, Meijo Hospital, 1-3-1 San-nomaru, Naka-ku, Nagoya 460-0001, 
      Japan. hiko0512@yahoo.co.jp
FAU - Umemoto, Yukihiro
AU  - Umemoto Y
FAU - Yasui, Takahiro
AU  - Yasui T
FAU - Saiki, Shigeru
AU  - Saiki S
FAU - Kuroda, Hideya
AU  - Kuroda H
FAU - Kotoh, Shuji
AU  - Kotoh S
FAU - Kamizaki, Hitonori
AU  - Kamizaki H
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - Japan
TA  - Int J Clin Oncol
JT  - International journal of clinical oncology
JID - 9616295
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Chromosome Aberrations
MH  - Chromosomes, Human, Pair 17/*genetics
MH  - Chromosomes, Human, Pair 9/*genetics
MH  - Female
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - *Neoplasm Invasiveness
MH  - *Neoplasm Staging
MH  - Sensitivity and Specificity
MH  - Urinary Bladder Neoplasms/*genetics/*pathology
MH  - Urine/cytology
EDAT- 2004/11/19 09:00
MHDA- 2005/02/08 09:00
CRDT- 2004/11/19 09:00
PHST- 2003/10/10 00:00 [received]
PHST- 2004/04/26 00:00 [accepted]
PHST- 2004/11/19 09:00 [pubmed]
PHST- 2005/02/08 09:00 [medline]
PHST- 2004/11/19 09:00 [entrez]
AID - 10.1007/s10147-004-0419-z [doi]
PST - ppublish
SO  - Int J Clin Oncol. 2004 Oct;9(5):373-7. doi: 10.1007/s10147-004-0419-z.